Table 1.

Comparison of 5‐FU dosing, clinical response and drug‐related toxicities between subset 1 and subset 2. Despite a marked reduction in dosing in subset 1, no difference in clinical outcome was observed between the groups

	Subset 1 (n = 15) PM patients Tailored 5‐FU	Subset 2 (n = 44) EM patients Standard 5‐FU
5‐FU total dose (mg)	2390 +/− 1225	3653+/− 1371	P = 0003 (t‐test)
Clinical benefit (CR + PR)	40%	43%	P = 0893 (Pearson's chi‐square)
Stable disease	40%	37%
Progressive disease	20%	20%
Early severe toxicities	0%	5%	P = 0104 Fisher's exact test
Early G1‐G2 toxicities	80%	86%
No early toxicities	20%	9%
Delayed severe toxicities	7%	7%

CR complete response; PR partial response.